Millennium Management LLC grew its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 369.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,281,629 shares of the company's stock after purchasing an additional 1,008,760 shares during the period. Millennium Management LLC owned approximately 1.81% of Ventyx Biosciences worth $2,807,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. increased its holdings in Ventyx Biosciences by 12.4% in the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock worth $147,000 after buying an additional 7,414 shares during the last quarter. Wells Fargo & Company MN raised its stake in Ventyx Biosciences by 23.3% during the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after acquiring an additional 7,768 shares in the last quarter. Barclays PLC raised its stake in shares of Ventyx Biosciences by 14.2% in the fourth quarter. Barclays PLC now owns 91,669 shares of the company's stock worth $200,000 after acquiring an additional 11,374 shares during the last quarter. Catalina Capital Group LLC bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $25,000. Finally, MetLife Investment Management LLC lifted its position in Ventyx Biosciences by 76.0% during the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock valued at $59,000 after purchasing an additional 11,543 shares during the period. Institutional investors own 97.88% of the company's stock.
Ventyx Biosciences Trading Down 2.7%
Shares of VTYX stock traded down $0.06 on Tuesday, hitting $1.99. 1,054,774 shares of the stock were exchanged, compared to its average volume of 1,356,320. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $5.66. The business has a 50-day moving average of $1.27 and a 200 day moving average of $1.72. The firm has a market capitalization of $141.25 million, a P/E ratio of -0.84 and a beta of 0.73.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. As a group, research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.
About Ventyx Biosciences
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
